Shen Qinglin, Peng Caixia, Zhan Yan, Fan Liang, Wang Mengyi, Zhou Qing, Liu Jue, Lv Xiaojuan, Tang Qiu, Li Jun, Huang Xiaodong, Xia Jiahong
Department of Oncology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China; Key Laboratory for Molecular Diagnosis of Hubei Province, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China.
Key Laboratory for Molecular Diagnosis of Hubei Province, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China; Central Laboratory, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China.
Int J Nanomedicine. 2016 May 18;11:2133-46. doi: 10.2147/IJN.S103569. eCollection 2016.
Selection of the optimal chemotherapy regimen for an individual cancer patient is challenging. The existing chemosensitivity tests are costly, time-consuming, and not amenable to wide utilization within a clinic. This limitation might be addressed by the recently proposed use of circulating tumor cells (CTCs), which provide an opportunity to noninvasively monitor response to therapy. Over the past few decades, various techniques were developed to capture and recover CTCs, but these techniques were often limited by a capture and recovery performance tradeoff between high viability and high efficiency. In this work, we used anti-epithelial cell adhesion molecule coated aptamer-poly (N-isopropylacrylamide) functionalized silicon nanowire substrates to capture and release epithelial cell adhesion molecule-positive CTCs at 32°C and 4°C, respectively. Then, we applied the nuclease to digest the aptamer to release the captured CTCs (near or at the end of the polymer brush), which cannot be released by heating/cooling process. High viability and purity CTCs could be achieved by decreasing the heating/cooling cycles and enzymatic treatment rounds. Furthermore, the time-saving process is helpful to maintain the morphology and enhance vitality of the recovered CTCs and is beneficial to the subsequent cell culture in vitro. We validated the feasibility of chemosensitivity testing based on the recovered HCC827 cells using an adenosine triphosphate-tumor chemosensitivity assay, and the results suggested that our method can determine which agent and what concentration have the best chemosensitivity for the culturing recovered CTCs. So, the novel method capable of a highly effective capture and recovery of high viability CTCs will pave the way for chemosensitivity testing.
为个体癌症患者选择最佳化疗方案具有挑战性。现有的化疗敏感性测试成本高、耗时,且不适合在临床广泛应用。最近提出使用循环肿瘤细胞(CTC)可能解决这一局限性,其为无创监测治疗反应提供了机会。在过去几十年中,开发了各种技术来捕获和回收CTC,但这些技术往往受到高活力与高效率之间捕获和回收性能权衡的限制。在这项工作中,我们使用抗上皮细胞粘附分子包被的适配体-聚(N-异丙基丙烯酰胺)功能化硅纳米线底物,分别在32°C和4°C下捕获和释放上皮细胞粘附分子阳性的CTC。然后,我们应用核酸酶消化适配体以释放捕获的CTC(接近或在聚合物刷末端),这些CTC不能通过加热/冷却过程释放。通过减少加热/冷却循环和酶处理轮次,可以实现高活力和高纯度的CTC。此外,节省时间的过程有助于保持回收的CTC的形态并增强其活力,有利于后续的体外细胞培养。我们使用三磷酸腺苷-肿瘤化疗敏感性测定法验证了基于回收的HCC827细胞进行化疗敏感性测试的可行性,结果表明我们的方法可以确定哪种药物和什么浓度对培养回收的CTC具有最佳化疗敏感性。因此,这种能够高效捕获和回收高活力CTC的新方法将为化疗敏感性测试铺平道路。